Background and Purpose: Lifarizine is a novel ion channel modulator which is neuroprotective in experimental global and focal ischemia, at doses that have minimal systemic vascular effects. This was a preliminary efficacy and safety study of lifarizine in human stroke. Methods: In a multicenter, randomized, double-blind, parallel-group study, subjects with symptoms and signs of first ischemic stroke were randomized to receive lifarizine (250 µg/kg, i.v. stat. plus 60 mg b.d. orally for 5 days) or matching placebo, after stratification for age (21–74 or ≥: 75 years) and for time since stroke onset (<6 or 6–12 h). Primary end points were safety of lifarizine and functional outcome at 13 weeks, using the modified Barthel Index and the Rankin Scale. Secondary measures included the National Institutes of Health and Canadian Neurological scales. Results: Of 147 patients recruited, 117 were evaluated for efficacy analysis. Lifarizine was well tolerated; a single seizure was attributed to active treatment. Biochemical and hematological indices were unchanged. Blood pressure fell over the study period, particularly in the lifarizine group. All-patient mortality during the 3-month study was 12/75 (16%) for lifarizine and 17/72 (24%) for placebo; amongst evaluable patients, mortality was 9/63 (14%) for lifarizine and 13/54 (24%) for placebo. At 13 weeks, the improvement in functional independence in the lifarizine group versus the placebo group was 16% greater by the Rankin Scale, p = 0.52, and 11% greater by the Barthel score, p = 0.55. Conclusions: Lifarizine was well tolerated. Mortality and functional assessment data showed favorable trends. Further studies are justified to examine the efficacy of lifarizine in acute stroke.

Keywords:
Lifarizine, Cerebral infarction
This content is only available via PDF.
© 1996 S. Karger AG, Basel
1996
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.